GSA Capital Partners LLP purchased a new stake in shares of Cardiovascular Systems Inc (NASDAQ:CSII) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 48,075 shares of the medical device company’s stock, valued at approximately $1,882,000.
A number of other institutional investors have also recently made changes to their positions in CSII. Partner Fund Management L.P. boosted its stake in Cardiovascular Systems by 49.9% during the second quarter. Partner Fund Management L.P. now owns 1,230,921 shares of the medical device company’s stock valued at $39,808,000 after buying an additional 409,767 shares during the last quarter. FMR LLC boosted its stake in Cardiovascular Systems by 187.0% during the second quarter. FMR LLC now owns 516,100 shares of the medical device company’s stock valued at $16,690,000 after buying an additional 336,300 shares during the last quarter. Millennium Management LLC boosted its stake in Cardiovascular Systems by 2,442.1% during the second quarter. Millennium Management LLC now owns 290,916 shares of the medical device company’s stock valued at $9,408,000 after buying an additional 279,472 shares during the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in Cardiovascular Systems during the third quarter valued at approximately $8,766,000. Finally, BlackRock Inc. boosted its stake in Cardiovascular Systems by 9.3% during the second quarter. BlackRock Inc. now owns 2,479,543 shares of the medical device company’s stock valued at $80,188,000 after buying an additional 210,128 shares during the last quarter. 80.02% of the stock is owned by institutional investors.
CSII has been the subject of a number of research reports. BidaskClub raised Cardiovascular Systems from a “hold” rating to a “buy” rating in a research note on Friday, August 10th. Stifel Nicolaus initiated coverage on Cardiovascular Systems in a research note on Wednesday, August 22nd. They set a “buy” rating and a $45.00 price target for the company. Zacks Investment Research lowered Cardiovascular Systems from a “hold” rating to a “strong sell” rating in a research note on Wednesday, September 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cardiovascular Systems in a research note on Wednesday, October 31st. Five equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Cardiovascular Systems presently has an average rating of “Buy” and an average price target of $35.20.
NASDAQ:CSII opened at $30.84 on Tuesday. The company has a market capitalization of $1.07 billion, a PE ratio of 616.80 and a beta of 2.36. Cardiovascular Systems Inc has a 1 year low of $20.58 and a 1 year high of $40.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.54 and a quick ratio of 4.04.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Tuesday, October 30th. The medical device company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). The company had revenue of $56.27 million during the quarter, compared to the consensus estimate of $55.96 million. Cardiovascular Systems had a net margin of 0.36% and a return on equity of 0.62%. Research analysts expect that Cardiovascular Systems Inc will post -0.09 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “GSA Capital Partners LLP Takes $1.88 Million Position in Cardiovascular Systems Inc (CSII)” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.com-unik.info/2018/12/04/gsa-capital-partners-llp-takes-1-88-million-position-in-cardiovascular-systems-inc-csii.html.
Cardiovascular Systems Profile
Cardiovascular Systems, Inc, a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral arterial disease products, including Diamondback 360 Peripheral, Predator 360, Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 60cm Peripheral OAS, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral, Diamondback 360 2.00 Peripheral, Diamondback 360 200cm Peripheral, and Diamondback 360 180cm Peripheral, which are catheter-based platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives.
Further Reading: Why do company’s buyback their stock?
Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems Inc (NASDAQ:CSII).
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.